- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
NICE: Pertuzumab Not Cost-Effective, Even When Used With Biosimilar Trastuzumab
The National Institute for Health and Care Excellence (NICE) evidence reviewers considered a biosimilar discount of 70% to 90% off the reference trastuzumab’s price at a 90% to a 100% market share, and the Cancer Drugs Fund provided the committee with confidential information on the weighted average price and market share for available biosimilar trastuzumab products.
Roche’s pertuzumab (Perjeta), a monoclonal antibody that is approved for use in combination with trastuzumab and docetaxel for the treatment of HER2-positive breast cancer, has once again been rejected by the United Kingdom’s National Institute for Health and Care Excellence (NICE) for adjuvant treatment of patients whose breast cancer has a high risk of recurrence.
While NICE, the United Kingdom’s health technology assessment body, had previously rejected the drug for routine National Health Service (NHS) use in this setting in June 2018, it agreed to reevaluate its decision in light of the cost savings that biosimilar versions of trastuzumab could provide to the overall treatment regimen.
Click here to read more about biosimilar trastuzumab in the United Kingdom.
Roche sells pertuzumab at a price of £2395 (approximately $3056) per 420-mg vial, and its brand-name trastuzumab, Herceptin, at a list price of £407.40 (approximately $520) per 150-mg vial. Roche also provides an undisclosed discount on pertuzumab to the NHS.
Biosimilar trastuzumab, which is now available in the United Kingdom, would reduce the overall cost of treatment, noted NICE, but even with deep discounts, it found that pertuzumab was unlikely to be cost-effective, largely because clinical trial results from the APHINITY trial “suggest that pertuzumab offers only a small incremental treatment benefit compared with placebo.”
NICE’s evidence reviewers considered a biosimilar discount of 70% to 90% off the reference trastuzumab’s price at a 90% to a 100% market share, and the Cancer Drugs Fund provided the committee with confidential information on the weighted average price and market share for available biosimilar trastuzumab products.
The reviewers determined that, after the weighted average biosimilar discount, the base-case incremental cost-effectiveness ratio (ICER) was £39,939 per quality-adjusted life year gained.
“Although the availability of biosimilar trastuzumab will greatly reduce the overall cost of the adjuvant pertuzumab regimen,” wrote NICE in its evaluation, the ICER “still does not fall within the range usually considered to be a cost-effective use of NHS resources.”
Once guidance is finalized, NICE will consider review of its position on pertuzumab in this setting after 3 years.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
